# A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

> **NCT07728188** · PHASE3 · NOT_YET_RECRUITING · sponsor: **AbbVie** · enrollment: 520 (estimated)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma

## Interventions

- **DRUG:** Etentamig
- **DRUG:** Pomalidomide
- **DRUG:** Daratumumab
- **DRUG:** Dexamethasone
- **DRUG:** Carfilzomib
- **DRUG:** Teclistamab

## Key facts

- **NCT ID:** NCT07728188
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11-30
- **Primary completion:** 2033-02
- **Final completion:** 2033-02
- **Target enrollment:** 520 (ESTIMATED)
- **Last updated:** 2026-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07728188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07728188, "A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07728188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*